Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:45:19.627Z.
Calculation as of: 2026-10-06T13:45:19.627Z.
Quote observation: 2026-10-06T13:45:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3dded1d9c7c97f6604bba9f83d6a77d690042e17e53b2ba4f54e500de5eb4a7b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$278.05M
Price/FCF Ratio
N/A
TTM Avg
2.52
3Y Avg
2.52
5Y Avg
2.52
Market Cap
$281.92M
Price/FCF Ratio
N/A
TTM Avg
56.97
3Y Avg
56.97
5Y Avg
56.97
Market Cap
$289.27M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.11M
Price/FCF Ratio
N/A
TTM Avg
39.34
3Y Avg
39.34
5Y Avg
39.34
Market Cap
$290.35M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurora Cannabis Inc. (ACB) | $277.81M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $278.05M | N/A | 2.52 | 2.52 | 2.52 |
| Fate Therapeutics, Inc. (FATE)vs › | $282.07M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | 56.97 | 56.97 | 56.97 |
| AC Immune S.A. (ACIU)vs › | $274.28M | N/A | 5.28 | 5.50 | 5.50 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.27M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $290.11M | N/A | 39.34 | 39.34 | 39.34 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.35M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $264.37M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
